UNSPSC 51433501: Quinuclium bromide

This classification denotes an antihypertensive agent with the molecular formula 2C14H18NO.2Br.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 502H53WMM0, chemically known as 1-methyl-3-oxo-4-phenyl-1-azoniabicyclo(2.2.2)octane, bromide but generally known as quinuclium bromide, which bears US NIH Compound Identifier 47458. European Medicines Agency schedules Quinuclium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10224MIG.

Most nations schedule quinuclium bromide under HS 29333999 and SITC 51574. As of Q4 2014, QUINUCLIUM BROMIDE remains the US FDA Preferred Term for this commodity. Quinuclium bromide bears US NLM identifiers UMLS ID C2825666 and NCI Concept Code C81522. SMILES: C[N+]12CCC(CC1)(C(=O)C2)C3=CC=CC=C3.[Br-].

UNSPSC 51433501 Quinuclium bromide is a Commodity code under which state and local governments procure advanced life support medications and pharmaceutical products for emergency medical services, healthcare systems, and multistate cooperative purchasing programs. Recent solicitations show state and local agencies buying specific medication formulations—epinephrine, labetalol, adenosine, diltiazem, and generic multi-source pharmaceuticals—in standardized units with strict expiration-date requirements, cold-chain handling, and FDA compliance. The issuing bodies span municipal fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department solicited sealed bids for Advanced Life Support Medications (Bid No. 26-P-00188) to supply Tampa Fire Rescue with 370 units of labetalol HCI 100mg vials, 1,810 units of epinephrine 1:10,000 injections, 330 units of adenosine 6mg vials, and 1,020 units of diltiazem 25mg vials, with a response deadline of April 8, 2026 and an estimated contract value of $40,000. That procurement included a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation and required vendors to warrant all materials free from defects for a minimum of 365 days, maintain nine-month minimum expiration dates, and deliver within ten calendar days of order receipt.

Recent activity concentrates in Florida and Minnesota. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued a Request for Proposal (RFP) for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and to maintain National Drug Code (NDC) documentation, cGMP certification, and Drug Supply Chain Security Act (DSCSA) compliance. The Texas Health and Human Services Commission issued a Request for Information (RFI) No. HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements, signaling exploratory state-level procurement strategy in the pharmaceutical supply chain. Vendors bidding under this code should expect firm-price requirements, detailed product specifications including NDC codes and expiration dates, compliance with federal and state accessibility standards (WCAG 2.2 Level AA, Section 508), OSHA Safety Data Sheets, and performance penalties for late reporting or missed onboarding timelines.